Aspire Biopharma Holdings Inc (ASBP) Stock Price, Quote & News

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testos...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 592 7399

Website: aspirebiolabs.com

Address:

23150 Fashion Drive, Suite 232, Estero, United States

ysg5804 Apr. 25 at 9:42 AM

$ASBP SES SST There is no friendship or love in the stock market. There is only money. Global ants have never experienced a sports day. They have nothing but worn-out brain structures.

0 · Reply

Arnie_510 Apr. 25 at 12:50 AM

$ASBP 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗣𝗨𝗠𝗣 𝗚𝗢𝗢𝗡 𝗔𝗧 𝗪𝗢𝗥𝗞 This character is so despetate to sell, I’ll bet he’s foaming at the mouth like a rabid dog. Or, he’s pimping for someone else, but we’ll never know because that would be a dead giveaway.

0 · Reply

KingAl_dino Apr. 25 at 12:06 AM

$ASBP Going to drop back to .16 next week then back up to .39

1 · Reply

TraderNice Apr. 24 at 9:37 PM

$ASBP A $3OM enterprise value for a business producing over $2OM in adjusted EBITDA would be a very low multiple, which can make the acquisition look highly accretive if the numbers hold. The fact that Aspire says it secured a $22.5M senior secured facility and does not expect a new equity raise also reduces the immediate dilution concern.

0 · Reply

MRC19 Apr. 24 at 9:21 PM

$ASBP back in 18,500 shares at .195

2 · Reply

TraderNice Apr. 24 at 8:20 PM

$ASBP Shorts is over their Head! ASBP, a small company, is trying to buy another company for $30 million. This is a lot of money for a company that’s only worth about $5 million. They’ve already filed a document with the Securities and Exchange Commission (SEC) and a non-binding agreement with the other company. They also have a 30-day no-shop period and $3.5 million break-up fees. This shows that both sides are serious about the deal. A lender has also given them a commitment letter for the loan, but it’s not final yet. If the deal goes through, the difference in value between the two companies could make a lot of money for ASBP.

0 · Reply

TraderNice Apr. 24 at 8:09 PM

$ASBP ASBP shorts are in a real pickle right now. With a borrowing rate of 191%, almost no shares left to borrow, and nearly 10% of the float already short, every hour they hold is costing them dearly. And guess what? Weekends don’t help matters either - fees keep piling up while the stock sits on a potential $30M acquisition catalyst. Shorts aren’t just underwater… they’re bleeding for every single day they stay in this situation.

0 · Reply

Arnie_510 Apr. 24 at 6:29 PM

$ASBP 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗣𝗨𝗠𝗣 𝗚𝗢𝗢𝗡 𝗔𝗧 𝗪𝗢𝗥𝗞 This character is so despetate to sell, I’ll bet he’s foaming at the mouth like a rabid dog.

0 · Reply

TraderNice Apr. 24 at 6:23 PM

$ASBP ASBP just punched through $0.2050 again - buyers are waking up and the wall is starting to crack. This thing is finally showing signs of life.

0 · Reply

TraderNice Apr. 24 at 6:20 PM

$ASBP YES! We are heading up….it’s happening

0 · Reply

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Apr 17, 2026, 8:00 AM EDT - 8 days ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Apr 16, 2026, 8:30 AM EDT - 9 days ago

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Apr 15, 2026, 8:00 AM EDT - 10 days ago

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Mar 19, 2026, 8:00 AM EDT - 5 weeks ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 17, 2026, 8:30 AM EDT - 5 weeks ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 12, 2026, 8:00 AM EDT - 6 weeks ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 10, 2026, 8:30 AM EDT - 6 weeks ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Feb 25, 2026, 8:30 AM EST - 2 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 20, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 19, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 17, 2026, 8:30 AM EST - 2 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 13, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 12, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 11, 2026, 7:45 AM EST - 2 months ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 10, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 5, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 3, 2026, 8:00 AM EST - 2 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Jan 29, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 27, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 22, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 21, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 20, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 14, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Announces Reverse Stock Split

Jan 7, 2026, 8:00 AM EST - 3 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Dec 18, 2025, 8:30 AM EST - 4 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 12, 2025, 5:00 PM EST - 4 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 4, 2025, 9:00 AM EST - 5 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Dec 2, 2025, 9:00 AM EST - 5 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Nov 26, 2025, 9:00 AM EST - 5 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 6, 2025, 9:00 AM EST - 6 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 3, 2025, 11:30 AM EDT - 7 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 2, 2025, 2:44 PM EDT - 7 months ago

Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher

Oct 1, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Sep 17, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 16, 2025, 8:30 AM EDT - 7 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 3, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 8 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 14, 2025, 8:00 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 13, 2025, 9:10 AM EDT - 9 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 31, 2025, 8:30 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 30, 2025, 7:45 PM EDT - 9 months ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 22, 2025, 10:45 AM EDT - 9 months ago

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Jul 9, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

Jun 24, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Jun 10, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

May 28, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 20, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

ysg5804 Apr. 25 at 9:42 AM

$ASBP SES SST There is no friendship or love in the stock market. There is only money. Global ants have never experienced a sports day. They have nothing but worn-out brain structures.

0 · Reply

Arnie_510 Apr. 25 at 12:50 AM

0 · Reply

KingAl_dino Apr. 25 at 12:06 AM

$ASBP Going to drop back to .16 next week then back up to .39

1 · Reply

TraderNice Apr. 24 at 9:37 PM

0 · Reply

MRC19 Apr. 24 at 9:21 PM

$ASBP back in 18,500 shares at .195

2 · Reply

TraderNice Apr. 24 at 8:20 PM

0 · Reply

TraderNice Apr. 24 at 8:09 PM

0 · Reply

Arnie_510 Apr. 24 at 6:29 PM

$ASBP 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗣𝗨𝗠𝗣 𝗚𝗢𝗢𝗡 𝗔𝗧 𝗪𝗢𝗥𝗞 This character is so despetate to sell, I’ll bet he’s foaming at the mouth like a rabid dog.

0 · Reply

TraderNice Apr. 24 at 6:23 PM

$ASBP ASBP just punched through $0.2050 again - buyers are waking up and the wall is starting to crack. This thing is finally showing signs of life.

0 · Reply

TraderNice Apr. 24 at 6:20 PM

$ASBP YES! We are heading up….it’s happening

0 · Reply

TraderNice Apr. 24 at 6:07 PM

$ASBP ASBP’s recent trading range shows little resistance above $0.21. If $0.2050 breaks cleanly, the stock has room to move. The current range ($0.19-$0.21) is super tight for a micro-cap. Any change in volume or sentiment can quickly break the stalemate.

0 · Reply

TraderNice Apr. 24 at 5:56 PM

$ASBP Shorts are in a tough spot heading into the weekend. Borrow fees don’t end on Saturday and Sunday, so every day they hold ASBP open, the cost keeps piling up. With borrow rates soaring to nearly 192% and almost no shares left to borrow, staying short through the weekend is going to be pricey.

0 · Reply

TraderNice Apr. 24 at 5:46 PM

$ASBP "ASBP keeps getting rejected at $0.2050 because that's where the sell wall is sitting - shorts and old holders are dumping right at that level. Once we clear $0.2050 with real volume, the chart opens up fast toward $0.22-$0.24 because there's almost no resistance above it. Breaking this level isn't about hype — it's about absorbing the wall so momentum can finally shift."

0 · Reply

TraderNice Apr. 24 at 5:39 PM

$ASBP come on break .2050!

0 · Reply

TraderNice Apr. 24 at 5:24 PM

$ASBP ASBP shorts are getting crushed right now. With a 191% borrow rate, almost no shares left to borrow, and nearly 10% of the float already short, every hour they hold is costing them. Weekends don't save them either - fees keep stacking while the stock sits on a potential $30M acquisition catalyst. Shorts aren't just underwater... they're bleeding for every day they stay in.

1 · Reply

TraderNice Apr. 24 at 5:21 PM

$ASBP ASBP is heating up….shorts! Borrow rate is sitting near 192%, short shares available are down to 100K, and about 430K shares are already sold short - almost 10% of the float. Shorts are paying a premium just to stay in the trade while retail is eyeing a tiny micro-cap chasing a $30M acquisition with real filings behind it. Tight supply, high borrow costs, and a potential deal catalyst make this one of those setups where momentum can flip fast depending on what drops next.

0 · Reply

TraderNice Apr. 24 at 4:59 PM

$ASBP ASBP, a small company, is trying to buy another company for $30 million. This is a lot of money for a company that’s only worth about $5 million. They’ve already filed a document with the Securities and Exchange Commission (SEC) and a non-binding agreement with the other company. They also have a 30-day no-shop period and $3.5 million break-up fees. This shows that both sides are serious about the deal. A lender has also given them a commitment letter for the loan, but it’s not final yet. If the deal goes through, the difference in value between the two companies could make a lot of money for ASBP. But if the deal doesn’t go through, the stock price could go down.

0 · Reply

Arnie_510 Apr. 24 at 4:42 PM

$ASBP 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝗔𝗹𝗹 𝗡𝗲𝘄 𝗕𝗮𝗴𝗵𝗼𝗹𝗱𝗲𝗿𝘀! The Bentley, Benz and Lambo payments are coming due!

0 · Reply

PhillyPhunk215 Apr. 24 at 4:29 PM

$ASBP it’s been consolidating nicely with strong support at .20 and trying to push up now. Let’s see what happens. Still in and heavy at .28 looking for a big bounce to get out

0 · Reply

Arnie_510 Apr. 24 at 4:03 PM

$ASBP 𝗪𝗛𝗔𝗧 𝗛𝗔𝗣𝗣𝗘𝗡𝗘𝗗 𝗧𝗢 𝗧𝗛𝗘𝗜𝗥 𝗦𝗨𝗕𝗟𝗜𝗡𝗚𝗨𝗔𝗟 𝗔𝗦𝗣𝗜𝗥𝗜𝗡? 🦗🦗🦗 𝗡𝗼𝘄 𝗮𝗹𝗹 𝗼𝗳 𝗮 𝘀𝘂𝗱𝗱𝗲𝗻 𝘁𝗵𝗶𝘀 𝗕𝗶𝗼𝗰𝗿𝗮𝗽 𝗵𝗮𝘀 𝗱𝗲𝗰𝗶𝗱𝗲𝗱 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝗔𝘂𝘁𝗼 𝗣𝗮𝗿𝘁𝘀 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀. 🚩

1 · Reply

Masterson83 Apr. 24 at 3:56 PM

$ASBP I see lots of posts from the same guy…anyone else with a take on this stock?

2 · Reply

TraderNice Apr. 24 at 3:38 PM

$ASBP The no-dilution part confirmed: The DCS acquisition is not expected to require a new equity raise — they plan to use the senior secured credit facility to finance it.

0 · Reply

Market Cap	1.08M
Revenue (ttm)	10,000.00
Net Income (ttm)	-24.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-244,800.00%
Debt to Equity Ratio	-0.44

Volume	4,950,600
Avg Vol	6,870,256
Day's Range	N/A - N/A
Shares Out	5.02M
Stochastic %K	4%
Beta	0.99
Analysts	Strong Buy
Price Target	N/A